PI3K/Akt/mTOR-IN-2 |
Catalog No.GC66463
One-Click Copy Product Info
|
PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2757804-89-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].
PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+[1].
Cell Proliferation Assay
| Cell Line: | PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells[1] |
| Concentration: | 0.5 - 100 μM |
| Incubation Time: | 72 hours |
| Result: | Exhibited effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM. |
Cell Cycle Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 24 hours |
| Result: | Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1. |
Apoptosis Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 24, 48 and 72 hours |
| Result: | Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners. |
Western Blot Analysis
| Cell Line: | MDA-MB-231[1] |
| Concentration: | 1 μM, 2 μM and 4 μM |
| Incubation Time: | 48 hours |
| Result: | Increased the expression of Bax, and decreased the expression of Bcl-2 |
| Cas No. | 2757804-89-8 | SDF | |
| Formula | C17H13F2NO | M.Wt | 285.29 |
| Solubility | DMSO : ≥ 100 mg/mL (350.52 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5052 mL | 17.526 mL | 35.0521 mL |
| 5 mM | 701 μL | 3.5052 mL | 7.0104 mL |
| 10 mM | 350.5 μL | 1.7526 mL | 3.5052 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)